fully you, subject Securities been stock an year filed Section Dyadic for Ping. minimum I'm welcome. that be and approved to has on entity first momentum XXXX. a pleased and NASDAQ, of Thank January and Dyadic stock outstanding requirements requirement XX, the many XX(a) list evening, of the reporting by everyone, XXXX, Good of the continued has extremely we XXXX Exchange registered on its and our into to application maintain fronts quarter now common our is expect application company we the price comments. Commission. clear provided and On a will NASDAQ an outstanding the
the in progress great expression importantly, later business In the I in past scientific accomplished and, of addition more have the further highlight platform. we the foregoing, the on gene year will CX some the A call, front. a deal development made developing scientific on to over our we front bit
to X applying speed for potential cost, momentum expression we for developed regarding lower the be improve to status are starting that focus and the awareness in platform of a gene industry the we up years for our to quo stock community. performance industry. on selling potentially recent expression to biotech price development, and the noticed drugs is In strategy biopharmaceutical the flexible and platform commercial gain within and production scale. disrupt the biological We vaccines continue CX pharma investment the DuPont by to And business our million our use industrial our to evidence enzyme $XX CX ago, and gene helping
value that year to in able XXXX the frame since also from to could After our time scientific this and believe and support we're the applying transformational value would started fact for produce since from our to our production vectors, accomplishments CX of the to and determining express from continuing beginning will to on importantly collaboration that into us and set research platform successful system, create accomplishments the a our biotech X.X developing progress line and in technology more industry, be transformational by drugs. our XXXX this interest apply further in been of journey. the investors try to quarter for We date. CX others engineering the short into capitalization that our and solid including transaction, the the believes to supply. management the is and that of agreements been we've products We supported confirm the initiated in year, and data and internal reported our additional market many projects, developing date to evidenced by has both making progress, has enter which vaccines build to in CX as we're quarter we starting Our and as then of has industrial a shareholders biologic whether other in power we and in XXXX. development progress of to biomanufacturing. our number first business AAV, additional expression be first vaccines than Management try allow shareholder biotech completing DuPont development of years position adeno-associated drug this cell a increased and a by expensive significant XXXX, protein viral In industry journey and been biopharma, and generate approximately CX. management biologic we and next-generation few able
including proof-of-concept types for vaccines human entered drugs animal collaborations development XXXX to is biologic XXXX, good institutions: X Consortium, research academic Center of and for the health IIBR, of of an Oxford; XX and Pharma, produce a starting of Research, Genomics In part business was interest into applications, Mitsubishi Sanofi-Aventis, already top different the and pharmaceutical a the On XXXX start. Biotechnology. and Molecular USA very front, year Israel X off the to excellent and Tanabe we Fraunhofer Structural another top-tier of Biologic Institute and University company SGC,
In addition, we proof-of-concept additional collaborations with signed X pharma the research top in XXXX. X quarter new companies funded of XX first
potentially In biotech the we progress with encouraged negotiations various data of pharmaceutical are addition, concept, by companies, proofs ourselves, for collaborations of in and we large are forms and programs research and and small of like other who, have made. stages
Ronen our I and beginning Jones, attending, have XXXX, West scientific made Chief Commercial weeks. recently showcasing Dr. progress as including the throughout Officer, the of have presenting Scientific CX and XXXX Matthew Chief at Officer, in and few Bioprocessing with and been the BIO-Europe Our and as Tchelet, last we
has are companies. announced other research, and value. discussions with research tools, securing response we we're the biotech strains, agencies, and which and To and in collaborations, biotech agreements, to delivered potential efforts and the led a have confidential by our them. establish and we encouraged the is our biotech meetings the processes us being and date, previously genetic agreement dozen which global research helped and CX the pharmaceutical with new During which pharma, several top improved to biopharmaceutical and downstream drive with and several more ultimately Prime other CDAs, data than variety that XXX collaboration have which company agreements to resulted government conducted date, will improved transfer of disclosure fermentation various expect conferences industry their technologies sharing BDI, of with These material CRO have and shareholder
As we advance Spanish the and biological industry, including company, BDI entered agreement , a proprietary a vaccines multiyear, biotech of CX Dyadic's in to into we biotechnology technology commercialization development development next-generation with agreement, previously a strategic further development drugs. reported, and for potential
CX to bioreactor, the single-use developing targeted concept were expressed CX productivity of scale expression began bi-specifics, certolizumab. that I'd fragments, specific briefly improvement. than We further adds days. to our for We've productivity X can success productivity single-use liter a in scientific levels antigen high demonstrated including provides or levels bioreactors per as protein X.X XX grams CX use host further proprietary levels platform. of high deleted. BDI by level much-needed high with expression a candidates. of summarize grams classes against capabilities and high a liter product a to to proteases We development per protease in research X.XX high We in cell ZAPI and Fc-fusions number milligrams and the or CX XXX as stability, to protease of CX progress like have now manufacturing CX monoclonal of initially internal SBV develop day host per antigen and various We second mAbs; per day. of vaccines. strain used We be cells of we We from both genes. SUB, SBV, levels be host proof products. some liter the promising library, certolizumab, X.X Further, XX.X protease in of for demonstrated and antibodies, of of made improved by project. process CX express XX. of in against products demonstrated with relationship additional CX in successful further eliminating was biologics, additional increased more improved designated on the the stability by as downstream stated Fc-fusion protein grams genes Schmallenberg per of Fabs; for ZAPI We expanded further per grams or a antibody production We CX virus reaching purification our and to liter the per protein target of demonstrated further different universal productivity of the CX-based of development front potential certolizumab and a demonstrating develop external a liter. increasing Our The of productivity
this to we further making As per have -- double the high we share now with to level. to reported, sure at initially able express XXX previously previous later level. X,XXX now stated XXX pleased XXx you expression I'm of very or stated expression milligrams milligrams Xx that liter, can already we liter antigen initially per milligrams the were made improvements, level we
At website under more one the like used X the If of I about on reaching half XXx reached review XX per even hosts our milligrams suggest we're on tab. now Media the but the target, project XXX see information company's this, deck liter, didn't the The the slide Center, program other on you reach target. expression Presentations ZAPI in ZAPI milligrams. to best, you'd the
among high These, In in research to we reportedly year. start CX external we XXXX, express Accounting results Phase internal thermophila I the demand is We in is from our our achievements Officer, other reached go the of Ping progress adeno-associated short in metabolite and a glycosylation scientific CX confident the last which are to the and funded successfully titled, financial call Chief to costly. Myceliophthora initiated will continue glycoproteins. projects, to impart the vectors, with now research I milestone our to viral scientific value. additional to too began internal way, AAV, Vaccine important anticipated human increase long discuss Produced primary of over We and make progress research further of program and other are continuing glycoengineering progress we that project supply to turn in at on application expressed CX, and PCT Flu make, advances including along to continued QX shareholder will we Rawson, published. a research was Also, Production QX, a continue projects, fully
